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ABSTRACT
Passive immunization with antibodies is a promising approach against enterotoxigenic Escherichia 
coli diarrhea, a prevalent disease in LMICs. The objective of this study was to investigate expression 
of a monoclonal anti-ETEC CfaE secretory IgA antibody in N. benthamiana plants, with a view to 
facilitating access to ETEC passive immunotherapy. SIgA1 and SIgA2 forms of mAb 68–81 were 
produced by co-expressing the light and engineered heavy chains with J chain and secretory 
component in N. benthamiana. Antibody expression and assembly were compared with CHO- 
derived antibodies by SDS-PAGE, western blotting, size-exclusion chromatography and LC-MS 
peptide mapping. N-linked glycosylation was assessed by rapid fluorescence/mass spectrometry 
and LC-ESI-MS. Susceptibility to gastric digestion was assessed in an in vitro model. Antibody 
function was compared for antigen binding, a Caco-2 cell-based ETEC adhesion assay, an ETEC 
hemagglutination inhibition assay and a murine in vivo challenge study. SIgA1 assembly appeared 
superior to SIgA2 in plants. Both sub-classes exhibited resistance to degradation by simulated 
gastric fluid, comparable to CHO-produced 68–61 SIgA1. The plant expressed SIgAs had more 
homogeneous N-glycosylation than CHO-derived SIgAs, but no alteration of in vitro functional 
activity was observed, including antibodies expressed in a plant line engineered for mammalian- 
like N glycosylation. The plant-derived SIgA2 mAb demonstrated protection against diarrhea in 
a murine infection model. Although antibody yield and purification need to be optimized, anti-ETEC 
SIgA antibodies produced in a low-cost plant platform are functionally equivalent to CHO anti-
bodies, and provide promise for passive immunotherapy in LMICs.
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Enterotoxigenic Escherichia coli (ETEC) causes 
severe diarrhea1, commonly in the first 2 y of life2. 
With estimates of several hundred million cases of 
diarrhea each year, mostly in low- and middle- 
income countries (LMICs), 3 ETEC is a leading 
cause of death among young children, with an 
estimated mortality of 300–500,000 in children 
under 5 y.4 ETEC is also estimated to cause 
approximately 10 million episodes of travelers’ 
diarrhea each year.5 A systematic review indicated 
that ETEC was detectable in 30–40% of travelers 
with diarrhea, particularly in endemic regions.6
ETEC is transmitted by the oro-fecal route 
through contaminated water or food. The primary 
control strategy is prevention of transmission 
through building sanitation infrastructure and 
basic food and water hygiene measures. In adults, 
ETEC diarrhea may be helped by a short course of 
antibiotics, but the development of antibiotic resis-
tance is increasingly reported.7,8
There is currently no commercial vaccine against 
ETEC. Vaccine development is challenging, due to 
antigenic diversity, including two enterotoxins 9 
and over 25 filamentous bacterial surface structures 
known as colonization factors and coli surface 
antigens.10 A killed whole cell vaccine (Dukoral®), 
primarily designed and licensed to prevent cholera, 
contains a recombinant B subunit of the cholera 
toxin that is antigenically similar to the heat labile 
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toxin of ETEC and has been recommended by 
some, 11 but a Cochrane review of twenty four 
randomized controlled trials did not provide suffi-
cient evidence to support this intervention.12
Promisingly, protective immunity to ETEC has 
been demonstrated after both natural and experi-
mental infection. In endemic areas, ETEC infection 
declines after 3 y of age suggesting acquisition of 
immunity, 13 and in human studies, subjects who 
recovered from ETEC diarrhea were protected 
against new infections with ETEC.14 Vaccine stra-
tegies have focused on eliciting anti-toxin antibo-
dies and anti-colonization factor immunity, as 
antibodies against both targets can contribute to 
protection.15,16 As ETEC infections are confined 
to the mucosal surfaces of the gut, it is generally 
considered that secretory IgA antibodies are likely 
to play an important role in immune protection.17 
In a piglet ETEC model, monoclonal IgA mixed 
into food was reported to prevent infection.18
CfaE is the minor subunit of CFA/I, one of the 
most important colonization factors expressed by 
pathogenic ETEC strains 19 and is responsible for 
adhesion to host intestinal epithelium. CfaE was 
previously shown to elicit protective antibodies 
that provided passive immunity against infection 
in animals and humans.20,21 Recently, the develop-
ment of a panel of 360 human monoclonal antibo-
dies (mAb) against CfaE was reported.22 Three of 
these that were class-switched and expressed as 
SIgAs were further tested in a murine ETEC colo-
nization model, and demonstrated a 2–4 log 
decrease in colony formation in comparison to 
animals treated with irrelevant SIgA controls.
With the aim of improving access to new SIgA 
products, in this study, we explore the feasibility of 
using anti-CfaE IgAs produced in plants, as oral 
immunotherapy for ETEC. Plants are increasingly 
attracting attention as a potential manufacturing 
platform for biologics like monoclonal antibodies 
and vaccines, 23 particularly those that are primarily 
needed in developing parts of the world. They offer 
important potential advantages, including low cost, 
massive scalability and rapid manufacture, as well 
as an opportunity to transfer technology to estab-
lish new manufacturing capacity in less developed 
regions.24 Several plant-made antibodies have 
already entered clinical trials.25,26 Plants were also 
the first heterologous expression system described 
for recombinant secretory IgA antibodies 27 and an 
early human clinical trial using an orally delivered 
SIgA produced in transgenic tobacco has been 
reported.28
We selected the most potent anti-CfaE SIgA, 
68–61 and manufactured this as recombinant 
SIgA1 and SIgA2 in Nicotiana benthamiana. The 
use of glycoengineered plant expression hosts has 
become standard in recent years to avoid glyco-
forms that are not usually found in humans, 29 so 
the use of such engineered lines was investigated 
here. The objective was to assess plant-produced 
SIgAs, comparing to SIgAs produced in CHO cells 
in respect to key preliminary evaluations of struc-
tural analysis, functional analysis of antigen bind-
ing and functional properties of SIgA.
Results
Plant secretory IgA assembly and identity
mAb 68–61 alpha1 or alpha2 heavy chain with 
kappa light chain was expressed with human 
J chain and secretory component by co-infiltration 
with the four relevant recombinant agrobacterium 
strains in N. benthamiana. Two N. benthamiana 
lines were used, one with unaltered (WT) plant 
glycosylation and another (ΔXF) in which glycosy-
lation is altered by deletion of xylosyl – and fucosyl- 
transferases.
After 5 d, total plant leaf extracts were pre-
pared and recombinant antibody was affinity pur-
ified. The samples were analyzed by non- 
reducing SDS-PAGE with silver staining and 
a representative result is shown in Figure 1a. 
Purified SIgA1 and SIgA2 antibodies prepared 
in CHO cell culture are shown for comparison. 
mAb 68–61 SIgA1 expressed in WT plants con-
tains a prominent band of the expected molecular 
size (arrow). Smaller prominent bands in the 
Mr90-200 K range are also detected, possibly 
representing assembly intermediates, which are 
also present in the CHO preparation. In the 
plant antibody samples, there were also 
a number of lower molecular weight bands 
(<Mr50K), which may represent degradation pro-
ducts. The SIgA2 sample resolved similarly to 
SIgA1. When expressed in the ΔXF plant line 
the major SIgA1 antibody bands appeared to 
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have faster mobility, possibly reflecting lower 
molecular weight. Detection of SIgA2 expressed 
from the ΔXF plant line was much reduced. The 
overall size and aggregation profile under non- 
denaturing conditions were evaluated by SEC.30 
Each SIgA sample displayed a heterogeneous 
mixture of molecular weight species including 
protein at the expected molecular weight for 
SIgA as well as various lower molecular weight 
species. In addition, higher molecular weight 
material was observed in all samples indicating 
the presence of some polymeric or aggregated 
material (Suppl Figure S1).
The identity of the protein bands in SDS-PAGE 
was confirmed by western blotting using specific 
antisera against the alpha heavy chain (panel B) or 
secretory component (panel C). Here, 
a commercial SIgA preparation purified from 
human colostrum (Sigma) was used as a positive 
control (SIgA std). The high molecular weight band 
assumed to represent SIgA1 was confirmed to 
include alpha chain and secretory component 
(SIgA1 ΔXF). No distinct band was observed at 
high molecular weight for plant SIgA2 (SIgA2 
ΔXF). The probability that the lower molecular 
weight bands observed in SDS-PAGE are assembly 
intermediates or degradation products was sup-
ported by their detection in the western blot using 
both anti-alpha chain and anti-SC. An extract from 
an untransformed plant served as a negative control 
and no cross-reactive proteins were identified (-ve 
plant extract).
LC-MS peptide mapping confirmed the presence 
of each of the polypeptide chains in the purified 
SIgA1 and SIgA2 samples. The results indicated 
88–99% coverage of the light chain in SIgA1 and 
SIgA2 from both WT and ΔXF plants, 60–72% 
coverage of the respective alpha heavy chains, 
48–88% coverage of the J chain and 41–61% cover-
age of the secretory component (data not shown).
Binding to cognate antigen
Recognition of specific ETEC CfaE antigen was 
determined by ELISA (Figure 2). ELISA plates 
were coated with the MBP-CfaE antigen and after 
blocking, incubation was with the four types of 
plant antibody (SIgA1 and SIgA2 from WT or 
ΔXF plants). Detection of binding was with anti- 
alpha, anti-kappa or anti-secretory component 
antisera. Here, the positive control was CHO- 
derived dimeric mAb 68–61 IgA (dIgA), which 
gave a positive signal when tested with anti-alpha 
and anti-kappa chain antisera, but not anti-SC anti-
serum as expected. The negative controls were PBS 
and nonspecific human colostral SIgA (HuIgA) 
which demonstrated no binding to ETEC antigen. 

























Anti- chain Anti – SCSIgA1 SIgA2a)
WT WTXF XF
Figure 1. Comparison of human ETEC 68–61 SIgA1 and SIgA2 prepared in CHO cells or plants. Non-reduced samples were separated by 
SDS-PAGE. (a) Silver stained polyacrylamide gel separating 2 or 5 µg of total protein per lane; (b) Western blot of plant produced 68–61 
SIgA1 and SIgA2. Detection with HRPO-labeled sheep anti-human alpha chain serum and DAB; (c) Western blot of plant antibodies and 
detection with mouse anti-secretory component serum, and fluorescein-labeled anti-mouse IgG serum. SIgA1 or SIgA2 were produced 
in CHO cells, wild-type (WT) or ΔXF tobacco as indicated. SIgA std is a polyclonal SIgA preparation from human colostrum. Arrows 
depict putative SIgA bands.
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samples was demonstrated using all antisera. 
Inconsistent binding by anti-J chain antiserum 
was detected (not shown), which has been reported 
previously by us and others.27,31
The yield of SIgA antibodies was determined by 
capture ELISA, using a standard curve derived 
from purified human colostral SIgA (not shown). 
Taking an average from three batches for each anti-
body, the yields of purified antibody/kg of fresh leaf 
tissue were: SIgA1 (WT N. benthamiana) – 7.1 mg; 
SIgA1 (ΔXF N. benthamiana) – 8.7 mg; SIgA2 (WT 
N. benthamiana) – 1.1 mg; and SIgA2 (ΔXF 
N. benthamiana) – 2.6 mg.
Glycoanalysis of CHO and plant-derived SIgA1 and 
SIgA2
A broad analysis of N-glycosylation in the CHO 
and plant-derived SIgA1 and SIgA2 mAbs was per-
formed using a rapid fluorescent/Mass spectrome-
try approach (Table 1). The results demonstrated 
greater heterogeneity in the N-linked glycoform 
species from CHO-derived antibodies than those 
from tobacco, particularly those of the complex 
glycan types. Glycans associated with SIgA1 and 
SIgA2 produced in the same host system were 
similar. As expected, some glycoforms were only 
associated with CHO manufacture and others with 
plant expression. For the latter, as expected, the 
XA1, XM3 and XA2 N-linked glycoform species 
were identified in WT N. benthamiana produced 
antibodies, but they were virtually absent in ΔXF 
N. benthamiana produced antibodies.
A more comprehensive glycoanalysis was per-
formed of the WT and ΔXF N. benthamiana pro-
duced SIgA1 and SIgA2 antibodies, using LC-ESI- 
MS. In this analysis, N-glycosylation sites on the 
alpha chains, J chain and secretory component 
were assessed quantitatively and individually as 
well as a potential O-glycosylation site on the 
alpha1 chain. Alpha1 heavy chains have two poten-
tial N-glycosylation sites and alpha2 heavy chains 
have four; J chain has one potential N-glycosylation 
site; and SC has five. The results were consistent 
with the findings from the Rapi-Fluor preliminary 
analysis. In addition, the analysis demonstrated 
that in the plant-produced SIgA1 antibodies, all 
potential N-glycosylation sites were occupied on 
the heavy and J chains, but no glycans could be 
detected associated with glycosites 1, 3 and 4 in 
secretory component (Suppl. Figure S2). Glycosite 
2 on the alpha1 chain was ~30% non-glycosylated, 
suggesting reduced accessibility of this site, com-
pared with glycosite 1. The major glycoforms are 
shown, with a preponderance of xylosylated (XA1) 
and xylosylated and fucosylated (FXA1, FXA2) gly-
coforms on the alpha chain and secretory compo-















Figure 2. Binding of anti-ETEC 68–61 SIgAs to MBP-CfaE antigen. Individual components of the SIgAs were detected by either anti- 
alpha chain, anti-kappa chain, or anti-Secretory Component antiserum. 1ug/mL anti-ETEC dimeric IgA (Mass. Biologics) was used as 
positive control. PBS and nonspecific human colostral SIgA (HuIgA) were used as negative controls. Plant extracts were loaded at 4-fold 
dilutions. Results are shown as mean+sd of triplicate assays.
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Table 1. Summary of N-glycosylation identification of 68–61 SIgA1 and SIgA2 produced in CHO, N. benthamiana and ΔXF 
N. benthamiana as measured by LC-MS glycan analysis. Check marks indicate observed N-glycosylation species from each 
individual SIgA sample. N-glycans are given according to the Consortium for Functional Glycomics notation; the Oxford glycan 
nomenclature was used for the abbreviations.
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antibodies, the results support the elimination of 
xylosylation and a significant knock-down of 
fucosylation.
The N-glycan profile of plant-produced SIgA2 was 
very similar to SIgA1 (Suppl. Figure S3). Glycosylation 
was not detected on the alpha2 chain at glycosites 1 and 
3. Glycosites 2 and 4 were modified almost identically 
to alpha1 chain glycosites 1 and 3, respectively. 
Interestingly, the glyco-engineering observed in the 
ΔXF plant host was highly consistent, resulting in vir-
tually the same glycan changes in alpha1 and alpha2 
chains. J chain was glycosylated very similarly in SIgA1 
and SIgA2 with the majority of glycoforms of the high 
mannose type. For SC, glycosylation at glycosites 1, 3 
and 4 was not detected. Site 2 was glycosylated but only 
at the limit of detection in our system, so detailed 
information is not provided. Glycosite 5 was the only 
site where clear data was obtained, and like J chain there 
was no difference between SIgA1 and SIgA2. For both 
J chain and SC, the effect of glyco-engineering in ΔXF 
plants was identical.
The proline residues of the O-glycosylation site of 
SIgA1 were partially oxidized to hydroxyprolines, 
which themselves were partially occupied by arabinose 
chains of varying length (Suppl. Figure S4). A relatively 
complex profile of peptide variants was present for the 
hinge region peptide of SIgA1 with no obvious differ-
ence between the plant wild type and ΔXF 
N. benthamiana produced antibodies.
Susceptibility of SIgAs to degradation under in vitro 
gastric digestion conditions
CHO and plant-produced SIgA1 and SIgA2 mAbs 
were subjected to pepsin digestion at pH 3.5 in 
modified simulated gastric fluid. Antibody degra-
dation was measured by a cfaE antigen binding 
ELISA (Figure 3). For the CHO-produced mAbs, 
SIgA1 appeared to retain more antigen binding 
ability after approximately 15 minutes of digestion 
with pepsin, compared to SIgA2, but there were no 
notable differences after 100 minutes. For the WT 
and ΔXF N. benthamiana produced antibodies, 
there were no notable differences in the digestion 
profiles of SIgA1 and SIgA2, which were both simi-
lar to the CHO SIgA1.
In vitro functional efficacy
The functional activity of different mAb 68–61 
preparations was compared using an ETEC adhe-
sion assay with Caco-2 cells (Table 2). The mini-
mum dose for 60% inhibition of cell adhesion was 
in the sub-microgram/ml levels for all samples. 
There was no notable difference between SIgA1 
and SIgA2 samples and the plant antibodies per-
formed as well as the CHO-produced antibodies.
A mannose-resistant hemagglutination assay of 
human erythrocytes was also performed with simi-
lar results. The minimum dose for 100% inhibition 
of ETEC induced hemagglutination was also in the 
sub-microgram/ml range and there were no differ-
ences between any of the SIgA antibody samples.
In both assays, there was no activity for irrele-
vant antibody controls.
In vivo protection against ETEC challenge
The protective efficacy of CHO-produced and 
plant-produced SIgA2 was next tested in a murine 
CHO SIgA1





Figure 3. In vitro gastric digestion model showing stability profiles of SIgA1 and SIgA2 produced in CHO cells and Nicotiana 
benthamiana. Comparison of cfaE-antigen binding for anti-cfaE mAbs (SIgA1 and SIgA2) after incubation in an in vitro gastric digestion 
model as measured by ELISA. The SIgA mAbs were produced in (a) CHO cells, (b) WT, and (c) ΔXF N. benthamiana. The relative percent 
of cfaE antigen binding remaining for each mAb was normalized to time zero binding. Each data point is displayed as the mean ± the 
data range; n = 2.
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infection model. 109 colony-forming units of ETEC 
strain H10407 were incubated with antibodies or 
PBS for 1 hour, before being administered in 100 μl 
volume by oral gavage to groups of eight C57BL/ 
6 mice. The readout was onset of diarrhea by 7 d 
post-infection and the results are shown in 
Figure 4. In the three groups where CHO- 
produced or plant-produced antibodies 68–61 
SIgA mAbs were used, only 37.5% of animals devel-
oped diarrhea and there was no difference between 
groups. In the control group, where no mAb was 
added, a significantly higher number, 75% of the 
mice developed diarrhea (p < .0001; two-tailed 
binomial test). None of the 12 non-challenged 
mice developed diarrhea.
Discussion
Passive immunization with anti-ETEC antibodies 
has been demonstrated in animal models32 and 
human volunteers.21 In the latter Phase I study, 
antibodies directed against the CFA/I minor pilin 
subunit (CfaE) protected against ETEC challenge, 
demonstrating that fimbrial tip adhesins are pro-
tective antigens. Importantly, the hyperimmune 
bovine IgG antibodies were delivered by the oral 
route, three times/day for one week, starting 2 
d prior to ETEC challenge, so these findings opened 
the way for development of improved and afford-
able orally delivered products.
For oral delivery, IgG antibodies are not optimal 
owing to their susceptibility to degradation at 
Table 2. In vitro activity against ETEC of 68–61 SIgA1 and SIgA2 produced in CHO, 
N. benthamiana and ΔXF N. benthamiana. The minimum dose for 60% inhibition of ETEC 
adhesion to Caco-2 cells is shown on the left side; the minimum dose for 100% 
inhibition of ETEC hemagglutination is shown on the right. Results are the mean of 
a minimum of three experiments.
SIgA1 SIgA2 SIgA1 SIgA2
Tobacco WT 0.15 0.22 0.156 0.078
Tobacco ∆XF 0.07 0.15 0.078 0.156
CHO 0.17 0.11 0.156 0.156
Non-specific -
ve control
Not detectable Not detectable >1.25 >1.25
Caco2 Cell Adhesion Assay               
(Min. dose for 60% inhibiton - µg/mL)
Haemagglu"na"on Assay                











































Figure 4. In vivo protection against ETEC challenge. Groups of 8 mice were inoculated with ~1x109 Escherichia coli (H10407) mixed with 
68–61 SIgA2 produced in N. benthamiana WT, ΔXF SIgA2 or CHO cells, or PBS only. In addition, a group of 12 mice were untreated and 
not infected. The percentage of mice developing diarrhea within 7 d is shown. Diarrhea was defined as unformed or watery stools 
occurring on any day of daily observations in each mouse.
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mucosal surfaces.28 Secretory (S)IgA antibodies are 
preferred. They are the major naturally occurring 
form of antibodies in mucosal secretions with spe-
cific adaptations for the mucosal environment. In 
humans, IgA exists as two subclasses, IgA1 and 
IgA2 both of which can assemble further into 
SIgA1 and SIgA2, respectively.33 Both are found 
in the gastrointestinal tract.34
These two IgA subclasses have arisen through 
gene duplication, and hence share considerable 
sequence similarity. The major structural difference 
is in the hinge region, where IgA1 features an 
extended hinge comprising two copies of an 8 
amino acid sequence, decorated with up to 6, 
O-linked oligosaccharides.35 The longer IgA1 
hinge may be an adaptation to enable higher avidity 
engagement with widely spaced antigens,36 but it 
also increases susceptibility to proteolytic attack.37
The extended hinge of IgA1 may not be the only 
important consideration in selecting antibody for-
mat. Other significant differences exist between 
IgA1 and IgA2, such as the extent of non-covalent 
binding of SC to IgA238 which may explain the 
difficulty that has consistently been experienced in 
expressing and purifying SIgA2. The different bind-
ing of SC to IgA1 and IgA2 was also shown to affect 
proteolytic degradation.
In this study, we compared SIgA1 and SIgA2 
versions of the same anti-ETEC antibody produced 
in CHO and N. benthamiana platforms. In 
N. benthamiana, the yield (1–9 mg/kg fresh leaf 
weight) was consistent with that of a human SIgA 
reported previously.31 IgG mAbs however can be 
expressed at yields of 400 mg/kg fresh leaf weight,39 
so further work is required to optimize expression 
of these anti-ETEC SIgAs in N. benthamiana.
The results suggest that the plant-produced SIgA 
antibodies are similar to antibodies expressed in 
CHO cells, with no differences in antigen recogni-
tion and binding, as expected. However, some dif-
ferences were noted and opportunities for 
improvements in product quality were identified. 
For example, increased low molecular weight 
impurities in the plant samples need to be 
addressed with optimized purification procedures 
to better remove trace proteases.40 In plants, SIgA1 
assembly appeared superior to that of SIgA2, parti-
cularly in the ΔXF plant line, although ELISA 
assays indicated the presence of fully assembled 
SIgA in both SIgA1 and SIgA2 samples. The appar-
ent difference between SIgA1 and SIgA2 assembly 
has been reported previously,38 and several factors 
could be involved. Differences in SC interactions 
with α1 and α2 heavy chains have been discussed 
above. There are also amino acid sequence differ-
ences between α1 and α2 chains throughout the 
constant region domains. Indeed, comparing the 
heavy chain sequences used here, there were 7 
amino acid differences in the Cα1 domain and 10 
amino acid differences in the Cα2 domain. The Cα3 
was identical, but the possibility that amino acid 
changes could result in cryptic targeting sequences 
affecting protein assembly, accumulation or stabi-
lity needs to be addressed further.
There was little functional difference between 
SIgA1 and SIgA2 either in the Caco2 cell adhesion 
assay or the hemagglutination assay. The SIgA2 was 
selected for the mouse challenge study because it is 
potentially a better clinical candidate with respect 
to stability and resistance to degradation in the gut 
environment. It demonstrated equivalent protec-
tion to that provided by CHO-produced SIgA2.
We also produced secretory mAbs in 
a glycoengineered N. benthamiana line,29 the ratio-
nale for which was the avoidance of β1-2 xylose and 
α1-3 fucose, which are non-human glycoforms. 
N-glycan analysis of the antibodies produced in 
ΔXF plants demonstrated a consistent elimination 
of xylosylation and virtually complete elimination 
of fucosylation. Importantly, neither of these two 
N-glycan modifications had any significant effect 
on antibody expression, biochemical analysis or 
protective efficacy.
Differences in glycosylation might also affect 
protein assembly efficiency and/or susceptibility 
to degradation. The overall glycan composition 
was identified with the unexpected finding that 
sialylated complex glycans were not observed in 
the CHO 68–61 SIgAs. Other CHO-produced 
SIgAs have been reported to be sialylated30 and 
sialylation can affect serum IgA mediated effector 
functions,41 so this result merits further study. 
Sialylation is not found in plants, although the 
pathway can be engineered.42 A more detailed 
site-specific analysis of the plant antibodies was 
performed. α1 heavy chains are commonly glyco-
sylated at two sites whilst α2 heavy chains are 
usually glycosylated at four. In this study, α1 
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heavy chain N-glycosylation sites were fully occu-
pied, whereas only two α2 heavy chain 
N-glycosylation sites (sites 2 and 4) appeared to 
be utilized. Furthermore, in contrast to our pre-
vious report with a different SIgA where 6 of the 7 
potential N-glycosylation sites on SC were occu-
pied, only 2 glycosites were found on SC in mAb 
68–61 SIgA1 and SIgA2. An important role of SC 
is to protect dimeric IgA from proteolytic 
degradation43 so resolving this discrepancy might 
also be a priority for future work.
α1 heavy chains also contain O-linked glycans. 
Three to six mucin-type O-glycans are commonly 
attached to the nine potential O-glycosylation sites 
in the hinge region of human IgA1.44 Our results 
confirmed the presence of typical plant-like 
O-glycosylation on all IgA1 samples, consisting of 
hydroxylated proline residues with attached arabi-
nose residues. Thus, it is also possible that assembly 
and stability of SIgAs is affected by O-linked sugars.
Conclusive evidence supporting the choice of 
either SIgA1 or SIgA2 for mucosal passive immu-
nization remains to be determined, but the ultimate 
goal of preventing ETEC disease in newly born 
children by passive oral immunization with specific 
monoclonal secretory antibodies may now be 
achievable. CHO cell-based manufacture of SIgAs 
is feasible, but it is unlikely that the CHO platform 
could ever be economically viable for an orally 
delivered product, particularly one targeted at neo-
nates in LMICs.45 Other groups that might benefit 
from a short-term use of orally delivered SIgA are 
travelers or military personnel.
This study indicates that protective anti-ETEC 
SIgA1 and SIgA2 antibodies can both be produced 
by N. benthamiana, and whilst further work is 
needed to consider best antigenic targets, the pos-
sibility of combining mAbs, to optimize alpha 
chain constant region sequences, maximize yields 
and establish more efficient extraction and purifica-
tion processes, this would be a requirement for any 
expression system. A long-term aspiration, requir-
ing more regulatory development, would be to 
express anti-ETEC secretory antibodies in edible 
plants, allowing direct administration by the oral 
route, as has been demonstrated by vaccine delivery 
using corn and potatoes for diarrheal and other 
diseases.46,47 This would simplify extraction and 
downstream processing, steps that are generally 
regarded as the major contributors to cost of 
goods.48,49
Materials and methods
Anti-ETEC mAb 68-61 gene constructs
The heavy and light variable region genes of mAb 
68–61 were codon optimized for Nicotiana, synthe-
sized (Geneart, USA) and cloned into pDONOR- 
based plasmids between a human Ig heavy chain 
leader sequence and human alpha 1 or alpha 2 
constant region, or a human light chain leader 
sequence and human kappa chain constant region. 
Full length heavy and light chain genes were sub- 
cloned into MIDAS entry vectors, containing the 
CaMV 35s double promoter before being combined 
into the pTRAK.6 destination vector. A pTRAK.6 
vector for both IgA1 and IgA2 was prepared, and 
introduced into Agrobacterium tumefaciens strain 
GV3101 PMP90/RK by electroporation.
Genes encoding human secretory component 
(SC) and J chain were synthesized and cloned into 
separate pEAQ-HT vectors.2 The pEAQ-HT vec-
tors were electroporated into Agrobacterium tume-
faciens strain LBA4404.
Vacuum infiltration with N. benthamiana
Agrobacteria containing appropriate constructs 
were grown overnight at 28°C in Lysogeny-Broth 
(LB), 100 µg/mL rifampicin, 50 μg/mL carbenicill-
lin and 5 µg/mL kanamycin for MIDAS constructs 
and 100 µg/mL rifampicin and 50 µg/mL kanamy-
cin for pEAQ-HT constructs. After centrifugation, 
the bacterial pellet was resuspended to OD600 with 
Infection Solution (IS; 0.01 mM MES and 0.01 mM 
MgCl2). The agrobacteria was introduced at a 2:4:1 
(alpha/kappa:J:SC) ratio into 6–8 week wild-type 
(WT) or glycoengineered ΔXF Nicotiana benthami-
ana 50 by vacuum infiltration.51 Plants were further 
grown in a controlled environment room at 25°C 
with 16/8 hour light/dark cycle.
Protein purification
Vacuum infiltrated leaves were harvested after 6 d. 
Leaf extracts were prepared with 3 volumes of PBS 
(pH8.0) with 0.1% Tween 20. Clarified crude 
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extracts were purified using Capto-LTM (GE 
Healthcare, USA) column. After washing, the pro-
tein was eluted with 0.1 M glycine-HCl (pH2.7) and 
neutralized with 1 M Tris-HCl (pH9.0). The anti-
body was dialyzed against PBS 0.01% Tween 20 
(Slide-A-Lyzer 100kDa; Thermo Scientific, USA) 
and concentrated using Amicon Ultra-15 (molecu-
lar cutoff 100kDa; Milipore, Ireland). The concen-
trations of purified antibodies were determined by 
ELISA.
PAGE gel and Western blot
Purified SIgAs were resolved on a NuPage 3–8% 
Tris Acetate gel (Life Technologies, UK) and 
stained with InstantBlue (Expedeon, UK). For the 
silver stained gel, samples were separated on 10% 
NuPAGE Bis-Tris gels (Life Technologies) and 
visualized using a silver stain kit (Thermo-Fisher). 
For Western blots, resolved gels were blotted onto 
nitrocelullose membrane (GE Healthcare, USA) 
and detected using 1:2500 goat anti-alpha chain- 
HRP (Sigma, USA), 1:2500 sheep anti-kappa chain- 
HRP (The Binding Site, UK), or 1:1000 mouse anti- 
SC (Sigma, USA) antisera, followed by 1:2000 
IRDye® 800CW goat anti-mouse IgG (LI-COR 
Biosciences, USA) or 1:1000 rabbit anti-J chain 
(Sigma, USA) antisera followed by 1:2000 anti- 
rabbit-HRP antiserum (The Binding Site, UK). 
Human colostrum SIgA (Sigma, USA) was used as 
positive control. Detection was performed using 
the ECL Prime system (Pierce, USA) and visualized 
using G:Box F3 (Syngene, UK).
Immunosorbent assays
For antibody characterization, 2 ug/mL MBP-CfaE 
was coated on ELISA plates overnight at 4°C. After 
blocking with 1% BSA in PBS/0.1% Tween 20, 
purified antibody samples were incubated with 
appropriate controls. Bound antibodies were 
detected with 1:1000 goat anti-alpha chain-HRP 
(Sigma, USA), 1:1000 sheep anti-kappa chain- 
HRP (The Binding Site, UK), 1:1000 mouse anti- 
SC (Sigma, USA) antisera, followed by 1:1000 goat 
anti-mouse IgG-HRP (Sigma, USA) or 1:1000 rab-
bit anti-J chain (Sigma, USA) antisera, followed by 
1:1000 anti-rabbit-HRP antiserum (The Binding 
Site, UK) followed by visualization with TMB 
substrate.
For antibody quantification, a similar assay was 
performed. ELISA plate coating was with 1:200 of 
mouse anti-SC antiserum (Sigma, USA) and detec-
tion was with 1:1000 sheep anti-kappa-HRP (The 
Binding Site, UK). Purified SIgA from human 
colostrum (Sigma, USA) was used to derive 
a standard curve.
LC-MS Peptide Mapping
LC-MS peptide mapping was performed as 
described elsewhere.30 Briefly, 50 μL of 1 mg/mL 
mAb samples were reduced and denatured with 
3 μL of 0.5 M DTT and 10 μL of 6 M guanidine 
hydrochloride, then alkylated with IAM prior to 
overnight trypsinization (~1:25 enzyme:mAb 
ratio) at 37°C. After trypsin inactivation, the sam-
ples were treated with PNGase F (New England 
BioLabs, Ipswich, MA). Prior to LC-MS, 0.05% (v/ 
v) trifluoroacetic acid was added, and samples were 
centrifuged for 5 min at 14,000 x g.
The peptides were separated by reversed phase 
UHPLC (Thermo Scientific) using a C18 column 
(1.7 μm, 2.1 × 150 mm, Waters Corporation). Mass 
spectrometry analysis was performed using a LTQ- 
XL ion trap (Thermo Scientific) and Xcalibur v2.0 
software (Thermo Scientific).30
N-Glycan Oligosaccharide analysis
N-Glycan oligosaccharide analysis was 
performed30 using the GlycoWorks RapiFluor- 
MS N-Glycan Kit (Waters Corporation, Milford, 
MA). Fluor-MS N-glycan analysis was performed 
using an Agilent 1260 Infinity II HPLC system 
equipped with a 1260 FLD detector and an 
Agilent 6230 electrospray ionization Time-of- 
Flight mass spectrometer (Agilent, Santa Clara, 
CA). A HILIC AdvanceBio Glycan Mapping col-
umn (120 Å, 2.1 × 150 mm, 2.7 μm), operated at 
45°C, was used to separate various N-glycans. 
Fluorescence was obtained using excitation and 
emission wavelengths of 265 and 425 nm, respec-
tively. MS was acquired simultaneously from 400 
to 2000 m/z at a constant scan rate of one spec-
trum per second. N-glycans were assigned based 
on m/z values using a N-glycan database (Water/ 
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NIBRT Glycan 3+) and N-glycan quantification 
was calculated on integration of the fluorescence 
chromatogram.
Site-specific glycosylation analysis was also per-
formed as described previously.52
Small scale, in-vitro model of gastric digestion and 
cfaE ELISA
The in vitro gastric digestion model to examine 
mAb stability was performed as described pre-
viously, 30 using simulated gastric fluid (94 mM 
NaCl, 13 mM KCl, 0.15 mM CaCl2 with 10 mM 
citrate-phosphate buffer pH 3.5). The reaction was 
started with 2000 U/mL pepsin (Sigma, US) and 
incubation was at 37°C for varying amounts of 
time. The reactions were neutralized by addition 
of 0.4 M NaOH and diluted to 1 μg/mL in ELISA 
blocking buffer (1% BSA in PBS) and stored at −20° 
C. ELISA was performed as described previously.22
CHO 68-61 SIgA and dIgA antibody production and 
characterization
68–61 SIgA2 antibody was produced and charac-
terized in CHO cells as previously described.22 
Antibody was purified by CaptoL resin (GE Life 
Sciences) followed by size exclusion chromatogra-
phy (HiLoad 26/600 Superdex 200 pg size exclusion 
column; GE Life Sciences).
Mannose-resistant hemagglutination assay of 
human group A erythrocytes
In a U-bottom 96-well plate (Nunc Thermo Scientific) 
SIgA antibodies were serially diluted 1:2 in duplicate 
and an equal volume of H10407 ETEC (ATCC35401) 
at an OD600nm of 1, was added to each well with 0.1 M 
D-mannose solution (Sigma, USA). After a 10 minute 
incubation at room temperature, human erythrocytes 
type A+ (BioreclamationIVT) were added to the plate 
at a final concentration of 1.5% (vol/vol) and mixed 
well. Hemagglutination was measured after 2 hours at 
4°C.
Analytical size exclusion chromatography
SEC was performed as described,30 using 
a Shimadzu Prominence ultra-fast liquid 
chromatography HPLC system. 10 µL of mAb 
(10 µg total protein) was injected and separated by 
a TSKgel G4000SWXL column (8 µm particle size, 
7.8 mm ID × 30 cm) with the corresponding guard 
column operated at ambient temperature (Tosoh 
Biosciences) using a 30-minute run time. Gel filtra-
tion molecular weight standards (Bio-Rad, 
Hercules, CA) were injected as controls. Data 
were analyzed using LC-Solutions software 
(Shimadzu, Kyoto, Japan).
Caco-2 adhesion assay
ETEC bacteria grown on CFA agar were resus-
pended to an OD690nm of 0.1. Caco-2 cells were 
seeded at 1 × 105 cells/mL in 24-well tissue cul-
ture plates containing Dulbecco’s modified 
Eagle’s medium at 37°C in 5% CO2. Antibody 
dilutions and bacteria were combined in a 1:10 
ratio and incubated for 1 hour at room tempera-
ture with shaking (300rpm), after which 0.2 mL of 
antibody/bacteria mixture was added to Caco-2 
cells. The plates were incubated for 3 hours at 37° 
C and the cells washed to remove non-adherent 
ETEC cells. Caco-2 cells were dislodged with 
0.25% trypsin, collected via centrifugation and 
resuspended in PBS. Dilutions were plated on 
CFA agar plates and colonies counted the 
next day. IC50 was defined as concentration of 
antibody needed to inhibit 50% of ETEC adhesion 
to the Caco-2 cells, compared to an irrelevant 
isotype antibody.
Murine model testing in vivo
Animal husbandry
The murine study according to recommendations 
in the Guide for the Care and Use of Laboratory 
Animals of the National Institutes of Health. The 
protocol was approved by the Committee on the 
Ethics of Animal Experiments of the University of 
Virginia (Protocol Number: 3315) in accordance 
with the Institutional Animal Care and Use 
Committee policies of the University of Virginia. 
All efforts were made to minimize suffering. Mice 
were male, 28 d old, C57BL/6 strain (Jackson 
Laboratories, ME), and maintained on a standard 
rodent diet (Harlan).
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Following a short acclimation period, the mice 
were given gentamicin (35 mg/L), vancomycin 
(45 mg/L), metronidazole (215 mg/L), and colistin 
(850 U/ml) in drinking water for 3 d.53 The mice 
were then given untreated water for 1 d, followed 
by a single oral challenge by gavage of ETEC.
Antibody treatment and ETEC infection
ETEC (H10407) cultures were grown from glycerol 
stocks in DMEM at 37°C in a shaking incubator.54 
Infected mice received an inoculum ~1x109 ETEC 
in 100 µL (90 µL antibody – approx. concentration 
3 mg/ml, or PBS + 10 µL DMEM); controls received 
100 µL of PBS alone.
Five groups (n = 8) were: Uninfected, ETEC 
+PBS, ETEC+CHO SIgA, ETEC+WT SIgA2, and 
ETEC+ΔXF SIgA2. The mice were euthanized 
on day 7 after infection.
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